| Literature DB >> 16979788 |
Sjoerd H van der Burg1, Martijn S Bijker, Marij J P Welters, R Offringa, Cornelis J M Melief.
Abstract
Soon after it was realized that T-cells recognize their target antigens as small protein fragments or peptides presented by MHC molecules at the cell surface, these peptide epitopes have been tried as vaccines. Human testing of such vaccines, although protective in mouse models, has produced mixed results. Since these initial trials, there has been an tremendous increase in our understanding of how infectious organisms can induce potent immune responses. In this article we review the key changes in the design, formulation and delivery of synthetic peptide vaccines that are applied to improve peptide vaccine strategies.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16979788 DOI： 10.1016/j.addr.2005.11.003
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 15.470